Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DNA + NYVAC + AIDSVAX
- Development stage
- Discontinued
- Lead developer
- National Institute of Allergy and Infectious Diseases
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
DNA + NYVAC + AIDSVAX is an investigational heterologous prime-boost HIV vaccine regimen. It consists of three distinct components: DNA-HIV-PT123 (a DNA plasmid vaccine), NYVAC-HIV-PT1 and NYVAC-HIV-PT4 (attenuated vaccinia virus NYVAC-vectored vaccines), and AIDSVAX B/E (a recombinant HIV-1 gp120 envelope glycoprotein subunit vaccine). The regimen is designed to elicit broad immune responses, including T-cell activation via the DNA and NYVAC primes and high-titer antibody responses targeting the HIV-1 Env V1/V2 regions via the AIDSVAX boost. Developed by the National Institute of Allergy and Infectious Diseases (NIAID), it was evaluated in the Phase 1 HVTN 101 trial for the prevention of HIV infection in healthy adults but the study was ultimately withdrawn.
- Brand names
- AIDSVAX B/E
- Other names
- DNA/NYVAC/AIDSVAX HIV vaccine regimen
02
Targets
Env (HIV-1 envelope glycoprotein)
Beyond the preview
Go deeper on DNA + NYVAC + AIDSVAX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DNA + NYVAC + AIDSVAX.